I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| classical monocyte | 8 studies | 19% ± 3% | |
| monocyte | 6 studies | 20% ± 5% | |
| neutrophil | 5 studies | 28% ± 9% | |
| macrophage | 4 studies | 20% ± 3% | |
| myeloid cell | 3 studies | 23% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| classical monocyte | 8 studies | 19% ± 3% | |
| monocyte | 6 studies | 20% ± 5% | |
| neutrophil | 5 studies | 28% ± 9% | |
| macrophage | 4 studies | 20% ± 3% | |
| myeloid cell | 3 studies | 23% ± 6% |
Insufficient scRNA-seq data for expression of OSM at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 643.97 | 575 / 578 | 80% | 8.32 | 920 / 1155 |
| kidney | 80% | 99.51 | 71 / 89 | 61% | 4.93 | 547 / 901 |
| breast | 62% | 62.31 | 283 / 459 | 65% | 4.49 | 728 / 1118 |
| bladder | 57% | 121.62 | 12 / 21 | 67% | 7.83 | 338 / 504 |
| adrenal gland | 84% | 139.13 | 218 / 258 | 37% | 3.25 | 86 / 230 |
| intestine | 49% | 45.50 | 475 / 966 | 71% | 9.17 | 375 / 527 |
| uterus | 45% | 38.91 | 76 / 170 | 68% | 5.61 | 311 / 459 |
| ovary | 44% | 36.93 | 80 / 180 | 63% | 4.55 | 273 / 430 |
| thymus | 61% | 64.65 | 396 / 653 | 47% | 2.78 | 285 / 605 |
| stomach | 37% | 49.80 | 133 / 359 | 68% | 7.69 | 194 / 286 |
| pancreas | 21% | 16.64 | 69 / 328 | 80% | 8.05 | 143 / 178 |
| spleen | 100% | 413.37 | 241 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 97% | 4304.87 | 903 / 929 | 0% | 0 | 0 / 0 |
| brain | 37% | 44.34 | 985 / 2642 | 56% | 5.90 | 394 / 705 |
| prostate | 58% | 56.61 | 142 / 245 | 29% | 1.45 | 145 / 502 |
| esophagus | 38% | 33.44 | 543 / 1445 | 45% | 2.77 | 83 / 183 |
| adipose | 81% | 190.49 | 972 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 5.30 | 35 / 45 |
| blood vessel | 72% | 127.82 | 956 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 69% | 8.61 | 20 / 29 |
| skin | 9% | 5.22 | 168 / 1809 | 48% | 3.24 | 227 / 472 |
| liver | 36% | 48.99 | 82 / 226 | 17% | 0.84 | 67 / 406 |
| heart | 48% | 50.87 | 414 / 861 | 0% | 0 | 0 / 0 |
| muscle | 3% | 2.16 | 27 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.03 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0046888 | Biological process | negative regulation of hormone secretion |
| GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0051781 | Biological process | positive regulation of cell division |
| GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
| GO_0038165 | Biological process | oncostatin-M-mediated signaling pathway |
| GO_0043410 | Biological process | positive regulation of MAPK cascade |
| GO_0006955 | Biological process | immune response |
| GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
| GO_1902036 | Biological process | regulation of hematopoietic stem cell differentiation |
| GO_0002675 | Biological process | positive regulation of acute inflammatory response |
| GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0050729 | Biological process | positive regulation of inflammatory response |
| GO_0032740 | Biological process | positive regulation of interleukin-17 production |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005147 | Molecular function | oncostatin-M receptor binding |
| GO_0008083 | Molecular function | growth factor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0005125 | Molecular function | cytokine activity |
| Gene name | OSM |
| Protein name | Oncostatin M Oncostatin-M (OSM) |
| Synonyms | |
| Description | FUNCTION: Growth regulator. Inhibits the proliferation of a number of tumor cell lines. Stimulates proliferation of AIDS-KS cells. It regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells. Uses both type I OSM receptor (heterodimers composed of LIFR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST). Involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneration (By similarity). . |
| Accessions | B5BUQ7 ENST00000403389.1 P13725 ENST00000215781.3 ENST00000403463.1 B5MC70 B5MCX1 |
